24,205 Shares in Zynex Inc. $ZYXI Purchased by Hsbc Holdings PLC

Hsbc Holdings PLC bought a new position in shares of Zynex Inc. (NASDAQ:ZYXI) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 24,205 shares of the company’s stock, valued at approximately $53,000. Hsbc Holdings PLC owned approximately 0.08% of Zynex as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Tower Research Capital LLC TRC increased its holdings in Zynex by 138.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,398 shares of the company’s stock worth $27,000 after buying an additional 1,975 shares during the last quarter. Alhambra Investment Management LLC acquired a new position in Zynex during the first quarter worth $30,000. Virtu Financial LLC acquired a new position in Zynex during the first quarter worth $39,000. Deutsche Bank AG increased its holdings in Zynex by 172.8% during the first quarter. Deutsche Bank AG now owns 19,796 shares of the company’s stock worth $44,000 after buying an additional 12,540 shares during the last quarter. Finally, Corton Capital Inc. acquired a new position in Zynex during the first quarter worth $52,000. Institutional investors own 29.68% of the company’s stock.

Zynex Stock Performance

ZYXI stock opened at $1.49 on Monday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.45 and a current ratio of 0.62. The company’s 50-day simple moving average is $1.97 and its 200 day simple moving average is $2.65. Zynex Inc. has a 52 week low of $1.23 and a 52 week high of $9.42. The company has a market capitalization of $45.15 million, a PE ratio of -1.59 and a beta of 1.02.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ZYXI shares. LADENBURG THALM/SH SH upgraded shares of Zynex from a “neutral” rating to a “buy” rating and set a $3.70 target price on the stock in a report on Friday, August 1st. Royal Bank Of Canada decreased their price objective on shares of Zynex from $4.00 to $3.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 15th. Finally, HC Wainwright downgraded shares of Zynex from a “buy” rating to a “neutral” rating in a report on Friday, August 1st. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $4.90.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.